News
MGC Pharmaceuticals (ASX:MXC) is a global biopharma company focused on developing and supplying high-quality phytotherapeutics and phytomedicines to patients in Europe, Australasia, and North America. The company’s current phytomedicine range includes CannEpil, an orally-administered medical cannabis treatment for drug-resistant (or refractory) epilepsy, and CogniCann, a treatment to improve quality of life in dementia patients. Both products are certified as Investigational Medical Products in the EU, and emerge from MGC’s euGMP formulation facility.
MGC has a full seed to pharma operation, from proprietary genetics through to the final phytomedicines undergoing clinical trials and produced under the strictest manufacturing conditions in the world. Because of this full hold on the supply chain, MGC is also a supplier of multiple phytocannabinoid products, from genetics via seed or tissue culture , through cosmetics and nutraceuticals, all the way to final medications, and phytocannabinoid active pharmaceutical ingredients (API).
MGC has established licensed growing operations in the Czech Republic and Slovenia, a fully GMP certified resin extraction plant in Slovenia, and was the first company approval from the Maltese government to build a local medical cannabis cultivation and production facility.
KEY PEOPLE

Nativ Segev – Founder, Director
Nativ Segev has more than 10 years of experience in implementation, legislation and lobbying in the global medical cannabis industry, combined with over 15 years of experience in various executive roles. Previously, he served as CEO of a leading medical cannabis company with a large patient base.

Roby Zomer - Founder, Managing Director
Roby Zomer has 10 years’ experience in the biotech and agtech sectors and joined MGC Pharmaceuticals as executive director and CTO. He brings extensive business contacts and his scientific and engineering skillsets to ensure MGC’s position as a leader in research and development.

Brett Mitchell – Executive Chairman
Brett Mitchell is a corporate finance executive with over 20 years of experience in the finance and resources industries. He has been involved in the founding, financing and management of both private and publicly-listed resource companies and holds executive and non-executive directorship roles.

Dr. Jonathan Gruenfeld – Chief Scientific Officer
Certified in Israel, with clinical experience in at the M.D. Anderson Cancer Center, Dr. Grunfeld has spent the past twenty years focusing on Neuro-Oncology, with a focus since 2010 on Cananabis as a treatment for oncological palliative care. He has directly been involved in the licensing and care of over 3000 medical cannabis patients in Israel, giving him a unique insight into questions of dosing, patient groups and developing treatment methodology.
RELATED STOCKHEAD STORIES
Health & Biotech
MGC Pharma delivers first batch order to Swiss PharmaCan, notches record sales quarter
Health & Biotech
MGC Pharmaceuticals receives go-ahead for Phase III trial of COVID-19 treatment
Health & Biotech
Huge shakeup expected as British American Tobacco makes a move on Canadian cannabis
Health & Biotech
Normal service is resuming for pot stocks as WSB buzz dies down
Health & Biotech
This cannabis ETF is still enjoying the wallstreetbets treatment
News
Last Orders: Small caps fall for 3rd day in worst loss this month
News
Closing Bell: Today’s Biggest Small Cap Movers on the ASX
Health & Biotech
MGC Pharma strikes exclusive world-wide product distribution agreement
Health & Biotech
Weed Week: Legal pot is a thing in Canberra — could NSW follow suit?
Health & Biotech
MGC Pharmaceuticals launches new clinical study into brain cancer treatment
Health & Biotech
MGC Pharma makes strong debut as London Stock Exchange’s first medicinal cannabis company
Health & Biotech
MGC Pharma is to become the first medicinal cannabis company to list on the London Stock Exchange
Stockhead TV
V-Con: Medical cannabis – green grass, green growth
Health & Biotech
MGC Pharma is soon to be admitted to the London Stock Exchange
Health & Biotech
MGC Pharma attracts $5m grant for its Malta-based production facility
Health & Biotech
MGC Pharmaceuticals confirms Phase II trial success for anti-inflammatory COVID treatment
News